On Demand 2021 Thursday Program

You can earn up to 7.25 AMA PRA Category 1 Credit(s)TM.

Price: FREE for College members who attended the annual meeting, $45 non-members

Allergists are increasingly referred rashes for evaluation and treatment. An integrated allergic and dermatologic approach to eczema, urticaria, contact dermatitis and drug eruptions allow us to extend our practice and lead to better outcome. The allergist is the expert on allergic dermatoses.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Describe the epidemiologic, clinical and genetic differences in atopic dermatitis patients with skin of color and of various age groups and use these differences to develop an optimal treatment plan
  • Describe current and emerging treatment strategies in managing moderate to severe atopic dermatitis
  • Describe the role of the JAK/STAT pathway in the pathogenesis of atopic dermatitis and to describe the use of JAK inhibitors to manage moderate to severe atopic dermatitis.
  • Implement a shared decision making process to help guide treatment plan development for patients with atopic dermatitis
  • Increase dermatologic rash diagnostic skills.
  • Reference and implement accurate details of updated guidelines.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance
Course opens: 
Course expires: 

Ama Alexis, MD

Marcella R. Aquino, MD, FACAAI

Donald V. Belsito, MD

Theresa A. Bingemann, MD, FACAAI

Michael S. Blaiss, MD, FACAAI

Mark Boguniewicz, MD, FACAAI

Timothy J. Craig, DO, FACAAI

Joseph F. Fowler, Jr., MD

Donald Y. Leung, MD, PhD, FACAAI

Kelly M. Maples, MD, FACAAI

Anil Nanda, MD, FACAAI

Karin A. Pacheco, MD, MSPH

Elizabeth J. Phillips, MD

Sarbjit S. Saini, MD

Marc Serota, MD

Ellen R. Sher, MD, FACAAI

Jonathan I. Silverberg, MD, PhD, MPH

Jonathan M. Spergel, MD, PhD, FACAAI

David R. Stukus, MD, FACAAI

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 7.25 AMA PRA Category 1 Credit™
  • 7.25 Attendance


Please login or create an account to take this course.